1021-25-6

Basic information

• Product Name: 1-PHENYL-1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE
• Synonyms: LABOTEST-BB LT00847564;1-PHENYL-1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE;1,3,8-Triazaspiro[4.5]decan-4-one, 1-phenyl-;spirodecanone;1-PHENYL-1,3 8-TRIAZASPIRO4,5DECAN-4-ONE 95%;1-Phenyl-1,3,8-triazaspiro4,5adecan- 4-one, 95%;3-Phenylspiro[imidazolidine-4,4'-piperidine]-5-one;1-Phenyl-1,3,8-triazaspiro[4.5]decan-4-one,95%
• CAS NO: 1021-25-6
• Molecular Formula: C₁₃H₁₇N₃O
• Molecular Weight: 231.29
• EINECS: 213-819-5
• Product Categories: AntagonistsHeterocyclic Building Blocks;Dopaminergics;N-Containing;Neurotransmitters;Others
• Mol File: 1021-25-6.mol
• Article Data: 4

Chemical Properties

• Melting Point: 188-191 °C
• Boiling Point: 373.38°C (rough estimate)
• Flash Point: 243.9 °C
• Appearance: beige to light brown powder
• Density: 1.0744 (rough estimate)
• Vapor Pressure: 2.31E-09mmHg at 25°C
• Refractive Index: 1.5700 (estimate)
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 15.08±0.20(Predicted)
• CAS DataBase Reference: 1-PHENYL-1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-PHENYL-1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE(1021-25-6)
• EPA Substance Registry System: 1-PHENYL-1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE(1021-25-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: 22-24/25
• WGK Germany: 3
• F: 10
• Hazardous Substances Data: 1021-25-6(Hazardous Substances Data)

Usage

Description

1-Phenyl-1,3,8-triazaspiro[4.5]decan-4-one is a chemical compound that serves as a metabolite of the long-acting neuroleptic agent Fluspirilene (F599800). It is also a basic metabolite formed from butyrophenone type agents and exhibits chemical properties as a beige to light brown powder.

Uses

Used in Pharmaceutical Industry:
1-Phenyl-1,3,8-triazaspiro[4.5]decan-4-one is used as a metabolite in the development and study of long-acting neuroleptic agents, specifically Fluspirilene (F599800). Its role in the metabolism of butyrophenone type agents contributes to understanding the pharmacokinetics and pharmacodynamics of these drugs, potentially leading to improved therapeutic options for various conditions.

InChI:InChI=1/C13H17N3O/c17-12-13(6-8-14-9-7-13)16(10-15-12)11-4-2-1-3-5-11/h1-5,14H,6-10H2,(H,15,17)/p+1

Upstream product

• 1096-03-3 1-benzyl-4-phenylaminopiperidine-4-carboxylic acid amide 
• 62-53-3 aniline 
• 968-86-5 1-benzyl-4-(phenylamino)piperidine-4-carbonitrile 
• 974-41-4 8-benzyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 974-42-5 1-(phenylmethyl)-4,4-(2-phenyl-2,4-diaza-4-oxo-cyclopentane)piperidine 

Downstream Products

• 3222-88-6 1-phenyl-8-<1-(p-chlorophenyl)ethyl>-1,3,8-triazaspiro<4.5>decan-4-one 
• 189209-03-8 8-[2-(4-Amino-3-nitro-phenyl)-ethyl]-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one 
• 754171-58-9 (-)-8-(5,8-Dichloro-1,2,3,4-tetrahydro-2-naphthyl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one 
• 1050-54-0 1-phenyl-8-(3-phenylpropyl)-1,3,8-triazaspiro[4.5]decan-4-one 
• 1054-89-3 8-[(4-oxo-4-phenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one 

Relevant articles and documents

Design, synthesis and biological evaluation of 2-arylaminopyrimidine derivatives bearing 1,3,8-triazaspiro[4,5]decan-4-one or piperidine-3-carboxamide moiety as novel Type-I1/2 ALK inhibitors

Aiming to develop novel Type-I1/2 inhibitors of ALK to overcome extensive resistance mutations, especially the L1196M mutation surrounding the ATP pocket, two series of 2-arylaminopyrimidine derivatives (11a-f and 22a-t) were designed based on scaffold hopping. The extensive structural elaboration discovered compound 22o which possessed excellent IC50 values of 0.06 and 0.23 μM against ALK-positive Karpas299 and H2228 cell lines, respectively. Meanwhile, 22o displayed encouraging inhibitory potency in the ALKWT (2.5 nM) and ALKL1196M (6.5 nM) enzymatic assays. Furthermore, the AO/EB and Hoechst 33258 assays illustrated 22o could induce cell apoptosis in a dose-dependent manner. Eventually, the molecular docking of 22o with ALK clearly presented the vital interactions within the active site, which was in accordance with Type-I1/2 inhibitor binding mode.

Discovery of Novel 1,3,8-Triazaspiro[4.5]decane Derivatives That Target the c Subunit of F1/FO-Adenosine Triphosphate (ATP) Synthase for the Treatment of Reperfusion Damage in Myocardial Infarction

Recent cardiology research studies have reported the role, function, and structure of the mitochondrial permeability transition pore (mPTP) and have shown that its opening plays a key role in the progression of myocardial cell death secondary to reperfusion. In this manuscript, we validated a new pharmacological approach as an adjunct to reperfusion in myocardial infarction (MI) treatment and describe the discovery, optimization, and structure-activity relationship (SAR) studies of the first small-molecule mPTP opening inhibitors based on a 1,3,8-triazaspiro[4.5]decane scaffold that targets the c subunit of the F1/FO-ATP synthase complex. We identified three potential compounds with good mPTP inhibitory activity and beneficial effects in a model of MI, including a decreased apoptotic rate in the whole heart and overall improvement of cardiac function upon administration during reperfusion. The selected compounds did not show off-target effects at the cellular and mitochondrial levels. Moreover, the compounds preserved the mitochondrial ATP content despite interacting with the ATP synthase complex.